3 results
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
PRIMARY OBJECTIVETo evaluate the time to first documented event of atrial fibrillation by 6 months continuous rhythm monitoring versus Standard of Care treatment in patients with a recent cryptogenic stroke or TIA without documented history of…
The primary objective is to influence amygdala and ventral striatum neuronal activity, thereby changing their influence on consequent approach/avoidance decisions, as indicated with left or right button presses.